N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=240 Comparison of A Mobile-Bearing Total Knee System With A Fixed-Bearing Total Knee System In Cemented Total Knee Arthroplasty
Degenerative Joint Disease
Primary: Maximum Knee Flexion — 110; 111; 111; 109.0 degrees — p=0.64
Phase 3 N=3,604 Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
Influenza
Primary: Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children — 407; 477; 768; 1293 Titers
Phase 3 N=11,404 Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
Influenza
Primary: Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains — 7; 9; 44; 2 Subjects — p=<0.001
Phase 3 N=2,418 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Safety Assessed by Adverse Events — 8.6; 7.8; 5.9; 4.9 percentage of participants
Phase 2 N=101 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
N/A N=8 Aquatic Treadmill Therapy for Improving Gait, Balance, Fitness and Quality of Life in Stroke Patients
Ischemic or Hemorrhagic Stroke · Hemiparesis
Primary: Safety — 0 adverse events
Phase 4 N=200 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery
Postoperative Complications
Primary: Serum Blood Glucose Concentrations — 101; 137; 140; 141 mg/dl
Phase 3 N=383 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
Pulmonary Arterial Hypertension
Primary: Frequently Reported (15% or More Overall) Adverse Events by Severity — 1; 20; 36; 0 participants
Phase 2 N=97 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants
Phase 2 N=15 Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
HIV Infections
Primary: Anti-Tat Antibody Titer — 401; 887 ng/mL
Phase 3 N=205 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain
Acute Ankle Sprain
Primary: Pain on Movement — 25.6; 61.2 mm
Phase 4 N=401 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Cerebral Infarction
Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants
Phase 3 N=583 Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
Epilepsy
Primary: Percentage of Participants Remaining in the Study at Each Visit — 95.6; 93.7; 87.6; 84.2 Percentage of Participants
N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants